Browse NXF2

Summary
SymbolNXF2
Namenuclear RNA export factor 2
Aliases TAP like protein 2
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus, nucleoplasm. Cytoplasm. Note=Localized in the nucleoplasm and at the nuclear envelope. Shuttles between the nucleus and the cytoplasm.
Domain PF02136 Nuclear transport factor 2 (NTF2) domain
PF09162 Tap
PF03943 TAP C-terminal domain
Function

Involved in the export of mRNA from the nucleus to the cytoplasm.

> Gene Ontology
 
Biological Process GO:0006403 RNA localization
GO:0006405 RNA export from nucleus
GO:0006406 mRNA export from nucleus
GO:0006913 nucleocytoplasmic transport
GO:0015931 nucleobase-containing compound transport
GO:0016973 poly(A)+ mRNA export from nucleus
GO:0050657 nucleic acid transport
GO:0050658 RNA transport
GO:0051028 mRNA transport
GO:0051168 nuclear export
GO:0051169 nuclear transport
GO:0051236 establishment of RNA localization
GO:0071166 ribonucleoprotein complex localization
GO:0071426 ribonucleoprotein complex export from nucleus
GO:0071427 mRNA-containing ribonucleoprotein complex export from nucleus
Molecular Function -
Cellular Component GO:0042272 nuclear RNA export factor complex
> KEGG and Reactome Pathway
 
KEGG hsa03008 Ribosome biogenesis in eukaryotes
hsa03013 RNA transport
hsa03015 mRNA surveillance pathway
Reactome R-HSA-74160: Gene Expression
R-HSA-72203: Processing of Capped Intron-Containing Pre-mRNA
R-HSA-72202: Transport of Mature Transcript to Cytoplasm
R-HSA-159236: Transport of Mature mRNA derived from an Intron-Containing Transcript
Summary
SymbolNXF2
Namenuclear RNA export factor 2
Aliases TAP like protein 2
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NXF2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between NXF2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
19401350Chronic lymphocytic leukemiaPromote immunity; immnuotherapy targetOur findings suggest that NXF2 could be further pursued as an immunotherapeutic target in CLL, and that treatment with demethylating agents could be exploited to specifically modulate CTA expression and effective antigen presentation in malignant B cells.
Summary
SymbolNXF2
Namenuclear RNA export factor 2
Aliases TAP like protein 2
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NXF2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNXF2
Namenuclear RNA export factor 2
Aliases TAP like protein 2
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NXF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.0050.29
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.2130.419
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7470.683
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.8880.315
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0160.992
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.7640.362
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0560.509
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NXF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277306.8-6.80.32
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275908.5-8.50.32
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNXF2
Namenuclear RNA export factor 2
Aliases TAP like protein 2
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NXF2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNXF2
Namenuclear RNA export factor 2
Aliases TAP like protein 2
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NXF2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NXF2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNXF2
Namenuclear RNA export factor 2
Aliases TAP like protein 2
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NXF2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNXF2
Namenuclear RNA export factor 2
Aliases TAP like protein 2
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NXF2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNXF2
Namenuclear RNA export factor 2
Aliases TAP like protein 2
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NXF2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNXF2
Namenuclear RNA export factor 2
Aliases TAP like protein 2
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NXF2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.